d-9

TrxR-IN-D9 is a novel inhibitor of thioredoxin reductase (TrxR).

L-838417 D9 (C-21191) 是 L-838417 的氘代物。其中L-838417 是亚型选择性GABAA 正变构调节剂，在 α2, α3 和 α5 亚型中作为部分激动剂。

Febuxostat D9 is deuterium labeled Febuxostat, which is a selective xanthine oxidase inhibitor with Ki of 0.6 nM.

Nadolol D9 is the deuterium labeled Nadolol is a blocker of non-selective beta.

Valsartan D9 is a deuterium-labeled valsartan. Valsartan is an antagonist of the angiotensin II receptor and for the treatment of high blood pressure and heart failure.

Desbutyl Lumefantrine D9, a deuterium-labeled metabolite of Lumefantrine, exhibits the incorporation of deuterium atoms.

CTP-656, a cystic fibrosis transmembrane conductance regulator (CFTR) channel activator, is used potentially for the treatment of cystic fibrosis.

Methyl -D9- choline is an isotopically labeled choline tracer.

Miglustat-d9 (hydrochloride)为Miglustat (hydrochloride)的氘代物，属于葡萄糖神经酰胺合成酶抑制剂，主要用于治疗I型戈谢病。

Choline-d9 chloride是Choline chloride的氘代标记物，可用于同位素示踪。Choline chloride是一种必需营养素，可激活α7烟碱受体，具有抗炎、镇痛的活性。

2-(5-tert-Butyl-2-hydroxyphenyl)benzotriazole-d9(2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4-(tert-butyl)phenol-d9) 是 2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4-(tert-butyl)phenol 的氘代物。

C-Met inhibitor D9 是一种c-Met 激酶抑制剂。

MDL-27048 is a powerful and reversible microtubule inhibitor.

Tebuconazole-d9 is intended for use as an internal standard for the quantification of tebuconazole by GC- or LC-MS. Tebuconazole is a triazole fungicide that is active against both seed and foliar fungi. It inhibits 14α-demethylase isolated from U. maydis and S. bicolor with IC50 values of 0.05 and 0.16 nM, respectively. It inhibits the androgenic effect of the androgen receptor agonist DHT (IC20 = 2.89 µM) and is cytotoxic (EC20 = 38.9 µM) in an MDA-kb2 assay. Tebuconazole (50 and 100 mg/kg per day) administered during gestation reduces testosterone levels and increases testicular levels of progesterone and 17α-hydroxyprogesterone in male rat fetuses. It has a feminizing effect on male pups and a virializing effect on female pups. When administered to rats gestationally through postnatal day 42, tebuconazole (20 and 60 mg/kg per day) leads to cell death of pyramidal cells in the CA3-4 region of the hippocampus and layer V of the cortex concomitant with impairment in learning......

Guaifenesin-d3 is intended for use as an internal standard for the quantification of guaifenesin by GC- or LC-MS. Guaifenesin is an expectorant. It inhibits production of mucin 5AC (MUC5AC), reduces mucus viscosity and elasticity, and increases the mucociliary transport rate of endogenous particles in primary human tracheobronchial epithelial cells in a concentration-dependent manner. Guaifenesin increases phenol red secretion, a marker of expectorant activity, in rats.3 Formulations containing guaifenesin have been used as expectorants in the treatment of the common cold and chronic bronchitis.

Phenylbutazone-d9 is intended for use as an internal standard for the quantification of phenylbutazone by GC- or LC-MS. Phenylbutazone is a non-steroidal anti-inflammatory drug and an inhibitor of the peroxidase activity of COX (IC50 = ~100 µM in the presence of hydrogen peroxide). It also inhibits prostaglandin I synthase (IC50 = ~25 µM in the presence of hydrogen peroxide). Phenylbutazone (2 mg/kg) reduces increases in type II collagen levels in the inflamed joints of an equine model of LPS-induced acute synovitis. Formulations containing phenylbutazone have been used in the treatment of lameness in horses.

G-33378 is a metabolite of sulfinpyrazone that inhibits human platelet cyclo-oxygenase activity.

1,3,7-Trimethyluric acid-d9 is intended for use as an internal standard for the quantification of 1,3,7-trimethyluric acid by GC- or LC-MS. 1,3,7-Trimethyluric acid is a derivative of uric acid and a metabolite of caffeine. It is formed from caffeine by the cytochrome P450 isoform CYP3A4. 1,3,7-Trimethyluric acid scavenges hydroxyl radicals in a cell-free assay and inhibits t-butyl hydroperoxide-induced lipid peroxidation by 56.5% in isolated human erythrocyte membranes.

hClpP-activator-D9 is a novel potent and species-selective activator of human ClpP (hClpP).

1-Palmitoyl-d9-2-hydroxy-sn-glycero-3-PA (1-palmitoyl-d9LPA) serves as an internal standard for the quantification of 1-palmitoyl LPA using GC- or LC-MS. This compound, an analog of LPA with palmitic acid at the sn-1 position, activates reporter gene expression in PC12 cells fitted with human lysophosphatidic acid receptor 4 (LPA4) at 0.01 to 10 µM concentrations. Additionally, 1-palmitoyl LPA prompts aggregation in isolated human platelets within the 12-300 µM range, a process reversible by prostaglandin E1 (PGE1), theophylline, or EDTA. It also interacts with calcium and magnesium to boost the efficacy of ampicillin, piperacillin, and ceftazidime against P. aeruginosa strains from cystic fibrosis patients.

1-1(Z)-Hexadecenyl-2-palmitoyl-d9-sn-glycero-3-PE serves as an internal standard for quantitating 1-1(Z)-hexadecenyl-2-palmitoyl-sn-glycero-3-PE, which is a plasmalogen incorporating 1(Z)-hexadecanoic acid and palmitic acid at the sn-1 and sn-2 positions respectively, in analyses performed using GC- or LC-MS.

1-Palmitoyl-d9-2-palmitoyl-sn-glycero-3-PE serves as an internal standard for the quantification of 1,2-dipalmitoyl-sn-glycero-3-PE (1,2-DPPE) using GC- or LC-MS. 1,2-DPPE, a prevalent PE (phospholipid), contains C16:0 fatty acids at the sn-1 and sn-2 positions and is essential in the inner plasma membrane leaflet. This compound forms a condensed lipid monolayer with cholesterol through tight hydrogen bonding between 1,2-DPPE headgroups, enhancing membrane fluidity to support transport and signaling.

1-Palmitoyl-d9-2-hydroxy-sn-glycero-3-PE serves as an internal standard for quantifying 1-palmitoyl-2-hydroxy-sn-glycero-3-PE, a lysophospholipid naturally found to inhibit L. donovani promastigotes growth (GI50= 8 µM). Its levels are reduced in mice after alcohol-induced liver damage, in hepatocellular carcinoma mouse xenografts, and in humans following a rigorous three-day exercise regimen of 2.5 hours running daily and 14 hours post-regimen. This compound is also applied in measuring saturated lysophosphoethanolamines, highlighting its broad utility in biochemical research and disease model studies.

1-Palmitoyl-d9-2-palmitoyl-sn-glycerol serves as an internal standard for quantifying 1,2-dipalmitoyl-sn-glycerol using GC or LC-MS techniques. This diacylglycerol, featuring palmitic acid at both the sn-1 and sn-2 positions, stimulates protein kinase C (PKC) activity by 15% at a 25 μM concentration. Additionally, 1,2-dipalmitoyl-sn-glycerol encourages rapid growth in Frankia, a genus of Gram-positive bacteria.